12 results on '"Ai Sheng Ho"'
Search Results
2. STAT3 exacerbates survival of cancer stem-like tumorspheres in EGFR-positive colorectal cancers: RNAseq analysis and therapeutic screening
- Author
-
Ai Sheng Ho, Yu-Cheng Chang, Ya Wen Chiang, Bi Ling Yang, Chun Chao Chang, Po Nien Liao, Yi Fang Chang, Ken-Hong Lim, Jungshan Chang, Ying Wen Su, Caleb Gon-Shen Chen, Huan Chau Lin, and Chun Chia Cheng
- Subjects
STAT3 Transcription Factor ,0301 basic medicine ,Colorectal cancer ,Endocrinology, Diabetes and Metabolism ,EGFR ,Clinical Biochemistry ,lcsh:Medicine ,Biology ,PDGFA ,STAT3 ,03 medical and health sciences ,Wnt ,LGR5 ,Cancer stem cell ,Epidermal growth factor ,medicine ,Humans ,Pharmacology (medical) ,Phosphorylation ,Wnt Signaling Pathway ,Molecular Biology ,Early Detection of Cancer ,Platelet-Derived Growth Factor ,Epidermal Growth Factor ,Sequence Analysis, RNA ,Research ,Biochemistry (medical) ,lcsh:R ,Wnt signaling pathway ,Cancer ,Cell Biology ,General Medicine ,medicine.disease ,ErbB Receptors ,Gene Expression Regulation, Neoplastic ,030104 developmental biology ,Homoharringtonine ,Neoplastic Stem Cells ,Cancer research ,Stem cell ,Colorectal Neoplasms ,HT29 Cells - Abstract
Background Cancer stem cells are capable of undergoing cell division after surviving cancer therapies, leading to tumor progression and recurrence. Inhibitory agents against cancer stem cells may be therapeutically used for efficiently eradicating tumors. Therefore, the aim of this study was to identify the relevant driver genes that maintain cancer stemness in epidermal growth factor receptor (EGFR)-positive colorectal cancer (CRC) cells and to discover effective therapeutic agents against these genes. Methods In this study, EGFR-positive cancer stem-like cells (CSLCs) derived from HCT116 and HT29 cells were used as study models for in vitro inductions. To identify the differential genes that maintain CSLCs, RNAseq analysis was conducted followed by bioinformatics analysis. Moreover, a panel containing 172 therapeutic agents targeting the various pathways of stem cells was used to identify effective therapeutics against CSLCs. Results RNAseq analysis revealed that 654 and 840 genes were significantly upregulated and downregulated, respectively, in the HCT116 CSLCs. Among these genes, notably, platelet-derived growth factor A (PDGFA) and signal transducer and activator of transcription 3 (STAT3) were relevant according to the cancer pathway analyzed using NetworkAnalyst. Furthermore, therapeutic screening revealed that the agents targeting STAT3 and Wnt signaling pathways were efficient in reducing the cell viabilities of both HCT116 and HT29 cells. Consequently, we discovered that STAT3 inhibition using homoharringtonine and STAT3 knockdown significantly reduced the formation and survival of HT29-derived tumorspheres. We also observed that STAT3 phosphorylation was regulated by epidermal growth factor (EGF) to induce PDGFA and Wnt signaling cascades. Conclusions We identified the potential genes involved in tumorsphere formation and survival in selective EGFR-positive CRCs. The results reveal that the EGF-STAT3 signaling pathway promotes and maintains CRC stemness. In addition, a crosstalk between STAT3 and Wnt activates the Wnt/β-catenin signaling pathway, which is also responsible for cancer stemness. Thus, STAT3 is a putative therapeutic target for CRC treatment. Electronic supplementary material The online version of this article (10.1186/s12929-018-0456-y) contains supplementary material, which is available to authorized users.
- Published
- 2018
3. EGFR-mediated interleukin enhancer-binding factor 3 contributes to formation and survival of cancer stem-like tumorspheres as a therapeutic target against EGFR-positive non-small cell lung cancer
- Author
-
Jungshan Chang, Kuei Fang Chou, Cheng Liang Peng, Nai Wen Su, Ying Wen Su, Chun Chia Cheng, Ken-Hong Lim, Cheng-Wen Wu, Yi Fang Chang, Ai Sheng Ho, Yu-Cheng Chang, Huan Chau Lin, Caleb Gon-Shen Chen, Bi Ling Yang, and Ya Wen Chiang
- Subjects
Male ,0301 basic medicine ,Pulmonary and Respiratory Medicine ,Cancer Research ,Lung Neoplasms ,Afatinib ,Mice, SCID ,Mice ,Random Allocation ,03 medical and health sciences ,0302 clinical medicine ,Mice, Inbred NOD ,Cancer stem cell ,Carcinoma, Non-Small-Cell Lung ,Cell Line, Tumor ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Animals ,Humans ,ERBB3 ,Molecular Targeted Therapy ,Epidermal growth factor receptor ,Phosphorylation ,Nuclear Factor 90 Proteins ,Lung cancer ,Protein Kinase Inhibitors ,biology ,business.industry ,Cell growth ,Imidazoles ,Cancer ,Drug Synergism ,medicine.disease ,Xenograft Model Antitumor Assays ,ErbB Receptors ,030104 developmental biology ,Oncology ,A549 Cells ,030220 oncology & carcinogenesis ,Cancer cell ,Neoplastic Stem Cells ,Cancer research ,biology.protein ,business ,Naphthoquinones ,medicine.drug - Abstract
Objectives YM155, an inhibitor of interleukin enhancer-binding factor 3 (ILF3), significantly suppresses cancer stemness property, implying that ILF3 contributes to cell survival of cancer stem cells. However, the molecular function of ILF3 inhibiting cancer stemness remains unclear. This study aimed to uncover the potential function of ILF3 involving in cell survival of epidermal growth factor receptor (EGFR)-positive lung stem-like cancer, and to investigate the potential role to improve the efficacy of anti-EGFR therapeutics. Materials and methods The association of EGFR and ILF3 in expression and regulations was first investigated in this study. Lung cancer A549 cells with deprivation of ILF3 were created by the gene-knockdown method and then RNAseq was applied to identify the putative genes regulated by ILF3. Meanwhile, HCC827- and A549-derived cancer stem-like cells were used to investigate the role of ILF3 in the formation of cancer stem-like tumorspheres. Results We found that EGFR induced ILF3 expression, and YM155 reduced EGFR expression. The knockdown of ILF3 reduced not only EGFR expression in mRNA and protein levels, but also cell proliferation in vitro and in vivo, demonstrating that ILF3 may play an important role in contributing to cancer cell survival. Moreover, the knockdown and inhibition of ILF3 by shRNA and YM155, respectively, reduced the formation and survival of HCC827- and A549-derived tumorspheres through inhibiting ErbB3 (HER3) expression, and synergized the therapeutic efficacy of afatinib, a tyrosine kinase inhibitor, against EGFR-positive A549 lung cells. Conclusion This study demonstrated that ILF3 plays an oncogenic like role in maintaining the EGFR-mediated cellular pathway, and can be a therapeutic target to improve the therapeutic efficacy of afatinib. Our results suggested that YM155, an ILF3 inhibitor, has the potential for utilization in cancer therapy against EGFR-positive lung cancers.
- Published
- 2018
4. STAT3 induces G9a to exacerbate HER3 expression for the survival of epidermal growth factor receptor-tyrosine kinase inhibitors in lung cancers
- Author
-
Ya Wen Chiang, Jungshan Chang, Ken-Hong Lim, Chun Chia Cheng, Ai Sheng Ho, Yi Fang Chang, and Zong Lin Sie
- Subjects
0301 basic medicine ,Male ,Cancer Research ,Lung Neoplasms ,Receptor, ErbB-3 ,Mice, SCID ,STAT3 ,Mice ,0302 clinical medicine ,Cell Movement ,Mice, Inbred NOD ,Histocompatibility Antigens ,Epidermal growth factor receptor ,Gene knockdown ,biology ,Kinase ,Imidazoles ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,ErbB Receptors ,Oncology ,030220 oncology & carcinogenesis ,Gene Knockdown Techniques ,Lung cancer ,Research Article ,STAT3 Transcription Factor ,G9a ,Cell Survival ,EGFR ,lcsh:RC254-282 ,03 medical and health sciences ,Downregulation and upregulation ,HER3 ,Genetics ,medicine ,Animals ,Humans ,Nuclear Factor 90 Proteins ,Protein Kinase Inhibitors ,Benzofurans ,BBI608 ,Cancer ,Histone-Lysine N-Methyltransferase ,medicine.disease ,Xenograft Model Antitumor Assays ,respiratory tract diseases ,MicroRNAs ,030104 developmental biology ,Tumor progression ,A549 Cells ,Drug Resistance, Neoplasm ,biology.protein ,Cancer research ,Naphthoquinones - Abstract
Background HER3 mediates drug resistance against epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs), resulting in tumor relapse in lung cancers. Previously, we demonstrated that EGFR induces HER3 overexpression, which facilitates the formation of cancer stem-like tumorspheres. However, the cellular mechanism through which EGFR regulates HER3 expression remains unclear. We hypothesized that EGFR downstream of STAT3 participates in HER3 expression because STAT3 contributes to cancer stemness and survival of EGFR-TKI resistant cancers. Methods First, RNAseq was used to uncover potential genes involved in the formation of lung cancer HCC827-derived stem-like tumorspheres. EGFR-positive lung cancer cell lines, including HCC827, A549, and H1975, were individually treated with a panel containing 172 therapeutic agents targeting stem cell-associated genes to search for potential agents that could be applied against EGFR-positive lung cancers. In addition, gene knockdown and RNAseq were used to investigate molecular mechanisms through which STAT3 regulates tumor progression and the survival in lung cancer. Results BBI608, a STAT3 inhibitor, was a potential therapeutic agent that reduced the cell viability of EGFR-positive lung cancer cell lines. Notably, the inhibitory effects of BBI608 were similar with those associated with YM155, an ILF3 inhibitor. Both compounds reduced G9a-mediated HER3 expression. We also demonstrated that STAT3 upregulated G9a to silence miR-145-5p, which exacerbated HER3 expression in this study. Conclusions The present study revealed that BBI608 could eradicate EGFR-positive lung cancers and demonstrated that STAT3 enhanced the expression of HER3 through miR-145-5p repression by G9a, indicating that STAT3 is a reliable therapeutic target against EGFR-TKI-resistant lung cancers.
- Published
- 2019
5. STAT3 Mediated miR-30a-5p Inhibition Enhances Proliferation and Inhibits Apoptosis in Colorectal Cancer Cells
- Author
-
Ai-Sheng Ho, Chun-Chao Chang, Wen-Chao Chen, Zong-Lin Sie, Chun-Chia Cheng, Hsin-Chi Lin, and Bi-Ling Yang
- Subjects
0301 basic medicine ,Colorectal cancer ,Apoptosis ,medicine.disease_cause ,lcsh:Chemistry ,STAT3 ,chemistry.chemical_compound ,0302 clinical medicine ,Cell Movement ,lcsh:QH301-705.5 ,Endoplasmic Reticulum Chaperone BiP ,Heat-Shock Proteins ,Spectroscopy ,biology ,miR-30a-5p ,General Medicine ,Computer Science Applications ,Gene Expression Regulation, Neoplastic ,030220 oncology & carcinogenesis ,Colorectal Neoplasms ,HT29 Cells ,STAT3 Transcription Factor ,Cell Survival ,colorectal cancer ,Article ,Catalysis ,Inorganic Chemistry ,03 medical and health sciences ,Regorafenib ,microRNA ,medicine ,Humans ,Viability assay ,HSPA5 ,Physical and Theoretical Chemistry ,Molecular Biology ,Cell Proliferation ,Organic Chemistry ,Cancer ,HCT116 Cells ,medicine.disease ,MicroRNAs ,030104 developmental biology ,lcsh:Biology (General) ,lcsh:QD1-999 ,chemistry ,STAT protein ,biology.protein ,Cancer research ,regorafenib ,Carcinogenesis - Abstract
Signal transducer and activator of transcription 3 (STAT3), a transcriptional factor involved in tumorigenesis and cancer stemness formation, contributes to drug resistance in cancer therapies. STAT3 not only mediates gene transcription but also participates in microRNA suppression. This study identified a STAT3-downstream micro RNA (miRNA) involved in drug resistance against regorafenib in colorectal cancer stem-like tumorspheres. Small RNAseq was used to investigate differential microRNAs in colorectal cancer cell-derived tumorspheres and in a STAT3-knockdown strain. The miRNA-mediated genes were identified by comparing RNAseq data with gene targets predicted using TargetScan. Assays for detecting cell viability and apoptosis were used to validate findings. The formation of colorectal cancer stem-like tumorspheres was inhibited by BBI608, a STAT3 inhibitor, but not by regorafenib. Additional investigations for microRNA expression demonstrated an increase in 10 miRNAs and a decrease in 13 miRNAs in HT29-derived tumorspheres. A comparison of small RNAseq results between tumorspheres and HT29shSTAT3 cells revealed the presence of four STAT3-mediated miRNAs in HT29-derived tumorspheres: hsa-miR-215-5p, hsa-miR-4521, and hsa-miR-215-3p were upregulated, whereas miR-30a-5p was downregulated. Furthermore, hsa-miR-4521 was associated with poor overall survival probability, and miR-30a-5p was associated with better overall survival probability in patients with rectum cancer. Comparisons of RNAseq findings between HCT116- and HT29-derived tumorspheres revealed that HSPA5 were mediated by the STAT3-miR-30a-5p axis, which is overexpressed in colorectal tumorspheres associating to anti-apoptosis. In addition, the transfection of miR-30a-5p and inhibition of HSPA5 by HA15 significantly reduced cell viability and increased apoptosis in HT29 cells. In conclusion, a STAT3-miR-30a-5p-HSPA5 axis was observed against regorafenib-mediated apoptosis in colorectal cancer tumorspheres. The expression of miR-30a-5p was repressed by STAT3, in addition, HSPA5 was identified as the target gene of miR-30a-5p and contributed to both tumorsphere formation and anti-apoptosis.
- Published
- 2020
6. Pravastatin inhibits tumor growth through elevating the levels of apolipoprotein A1
- Author
-
Chun-Chia Cheng, Ai-Sheng Ho, Jungshan Chang, Hua-Ching Lin, Tsai-Yueh Luo, and Chun Yeh
- Subjects
0301 basic medicine ,Colorectal cancer ,Inflammation ,Pharmacology ,03 medical and health sciences ,chemistry.chemical_compound ,Medicine, General & Internal ,0302 clinical medicine ,polycyclic compounds ,medicine ,Doxorubicin ,Pravastatin ,biology ,Cholesterol ,business.industry ,nutritional and metabolic diseases ,Cancer ,General Medicine ,medicine.disease ,030104 developmental biology ,chemistry ,030220 oncology & carcinogenesis ,biology.protein ,Apolipoprotein A1 ,lipids (amino acids, peptides, and proteins) ,medicine.symptom ,Gastric cancer ,business ,medicine.drug ,Lipoprotein - Abstract
Summary Background Statins are a class of drugs used to lower cholesterol levels, accompanying increased high-density lipoprotein (HDL) levels. Previous studies have suggested that statins can inhibit inflammation, and also reduce tumor proliferation. We therefore hypothesized that pravastatin, a member of the statins, mediating the inhibitory functions in tumor growth may be associated with the upregulated HDL constituent, apolipoprotein A1 (ApoA1). Methods Pravastatin-induced inhibition in tumor proliferation in vitro and in xenografts was investigated. Reduced ApoA1 expressions were detected in the tumor regions in specimens from tumor patients as well in xenografts using Western Blotting. Moreover, ApoA1 was administered to inhibit tumor proliferation, and pravastatin was given to enhance the chemotherapeutic efficacy of doxorubicin (DOX). Results We found a significant statistical reduction of ApoA1 in the tumor regions of specimens from gastric cancer and colorectal cancer patients. MKN45 cells proliferation was inhibited by 18% under the growing medium containing pravastatin. ApoA1 levels were elevated in liver Clone 9 cells administered pravastatin, but not in MKN45 cells. In vitro studies revealed that ApoA1 can reduce MKN45 tumor proliferation. Moreover, the tumor volume was significantly reduced in in vivo xenografts after the administration of pravastatin. Combined treatments of pravastatin with DOX significantly minimized the size of tumors, leading to a better therapeutic efficacy. Conclusion This study demonstrated that pravastatin elevated ApoA1, an HDL major constituent with anti-inflammatory characteristics, which displayed strong adversary associations with tumor developments and growth. Increasing the amounts of ApoA1 by pravastatin coupled with DOX may improve the therapeutic efficacy for cancer treatment.
- Published
- 2015
7. Afatinib and its encapsulated polymeric micelles inhibits HER2-overexpressed colorectal tumor cell growthin vitroandin vivo
- Author
-
Cheng Tien Wu, Chun Chia Cheng, Shing-Hwa Liu, Ai Sheng Ho, Jungshan Chang, Tsai Yueh Luo, Siao Syun Guan, and Chia-Chi Wang
- Subjects
Adult ,Male ,Oncology ,medicine.medical_specialty ,micelles ,Cell Survival ,Polymers ,Receptor, ErbB-2 ,Colorectal cancer ,Drug Compounding ,Afatinib ,Immunoblotting ,afatinib ,Mice, Nude ,colorectal cancer ,Apoptosis ,In vivo ,HER2 ,Cell Line, Tumor ,Internal medicine ,medicine ,Animals ,Humans ,skin and connective tissue diseases ,neoplasms ,Aged ,Cell Proliferation ,Mice, Inbred BALB C ,business.industry ,Cell growth ,Therapeutic effect ,Cancer ,Hep G2 Cells ,Middle Aged ,Hepatology ,medicine.disease ,Xenograft Model Antitumor Assays ,digestive system diseases ,In vitro ,Tumor Burden ,MCF-7 Cells ,Quinazolines ,Female ,Colorectal Neoplasms ,business ,Research Paper ,medicine.drug - Abstract
// Siao-Syun Guan 1,2 , Jungshan Chang 3 , Chun-Chia Cheng 2,3 , Tsai-Yueh Luo 2 , Ai-Sheng Ho 4 , Chia-Chi Wang 5 , Cheng-Tien Wu 1 and Shing-Hwa Liu 1,6,7 1 Institute of Toxicology, College of Medicine, National Taiwan University, Taipei, Taiwan 2 Institute of Nuclear Energy Research, Atomic Energy Council, Taoyuan, Taiwan 3 Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei, Taiwan 4 Division of Gastroenterology, Cheng Hsin General Hospital, Taipei, Taiwan 5 Division of Hepatology, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation and School of Medicine, Tzu Chi University, Hualien, Taiwan 6 Department of Medical Research, China Medical University Hospital, China Medical University, Taichung, Taiwan 7 Department of Pediatrics, National Taiwan University Hospital, Taipei, Taiwan Correspondence: Shing-Hwa Liu, email: // Keywords : colorectal cancer / HER2 / afatinib / micelles Received : March 31, 2014 Accepted : May 30, 2014 Published : June 1, 2014 Abstract Colorectal cancer (CRC) is known as a common malignant neoplasm worldwide. The role of EGFR/HER2 in CRC is unclear. Afatinib is an irreversible EGFR/HER2 inhibitor. There were few studies of afatinib on CRC. Here, we investigated the protein levels/expressions of HER2 in sera and tumors from CRC patients and the therapeutic effect of afatinib on HER2-overexpressed CRC in vitro and in vivo . The increased HER2 levels were detected in the collected sera and tumors of patients with CRC. The serological HER2 levels were correlated with the tumor HER2 expressions in patients. Afatinib also inhibited the HER2-positive tumor cell growth and caused apoptosis in HER2-overexpressed human colorectal cancer HCT-15 cells but not in low HER2 expressed human gastric cancer MKN45 cells. In vivo study showed that afatinib reduced tumor growth in HER2-overexpressed xenografts. Moreover, afatinib-encapsulated micelles displayed higher cytotoxic activity in HCT-15 cells and were more effective for tumor growth suppression in HCT-15-induced tumor xenografts than afatinib performance alone. Taken together, these findings suggest that higher serum HER2 levels reflect the higher HER2 contents in tumors of CRC patients, and the improved afatinib-encapsulated micelles possess high therapeutic efficacy in HER2-overexpressed CRC in vitro and in vivo .
- Published
- 2014
8. Abstract 3028: STAT3 represses miR-145-5p to exacerbate HER3 expression for surviving EGFR-TKIs in lung cancers
- Author
-
Ken-Hong Lim, Ya-Wen Chiang, Jungshan Chang, Chun-Chia Cheng, Ai-Sheng Ho, and Yi-Fang Chang
- Subjects
Cancer Research ,Gene knockdown ,biology ,business.industry ,Cancer ,medicine.disease ,respiratory tract diseases ,Oncology ,Downregulation and upregulation ,Tumor progression ,Cancer research ,biology.protein ,medicine ,Epidermal growth factor receptor ,STAT3 ,Lung cancer ,business ,Tyrosine kinase - Abstract
HER3 exerts resistance against epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), resulting in tumor relapse in lung cancers. Previously, we have demonstrated that EGFR induces HER3 overexpression and that contributes to the formation of cancer stem-like tumorspheres. However, the cellular mechanism of EGFR in regulating HER3 expression was obscure. We hypothesized that EGFR-downstream STAT3 participates in HER3 expression since STAT3 contributes to cancer stemness and surviving EGFR-TKIs. First, RNAseq was used to uncover the potential genes involving in formation of lung cancer HCC827-derived stem-like tumorspheres. EGFR-positive lung cancer cell lines (HCC827, A549, H1975) were individually treated with a panel containing 172 compounds which targeting to stem cell-associated genes in order to searching potential agents against EGFR-positive lung cancers. In addition, gene knockdown and RNAseq were used for investigating the molecular mechanism of STAT3 on regulating tumor progression and survival of lung cancers. We found that BBI608, a STAT3 inhibitor, was a potential therapeutic agent specifically reducing the cell viability of EGFR-positive lung cancers. Interestingly, the inhibitory effects caused by BBI608 were similar with that derived from YM155, an ILF3 inhibitor, both compounds reduced G9a-mediated HER3 expression. We, furthermore, demonstrated that STAT3 upregulated G9a to silence miR-145-5p for exacerbating HER3 expression in this study. In conclusion, this study figured out the potential cellular function of STAT3 in EGFR-positive lung cancers. We also evaluated that BBI608 was potential to eradicate EGFR-positive lung cancers and demonstrated that STAT3 regulated expression of HER3, indicating that STAT3 was a reliable therapeutic target against EGFR-TKI-resistant lung cancers. Note: This abstract was not presented at the meeting. Citation Format: Chun-Chia Cheng, Ya-Wen Chiang, Ken-Hong Lim, Jungshan Chang, Ai-Sheng Ho, Yi-Fang Chang. STAT3 represses miR-145-5p to exacerbate HER3 expression for surviving EGFR-TKIs in lung cancers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3028.
- Published
- 2019
9. Novel targeted nuclear imaging agent for gastric cancer diagnosis: glucose-regulated protein 78 binding peptide-guided 111In-labeled polymeric micelles
- Author
-
Tsai Yueh Luo, Jungshan Chang, Cheng Liang Peng, Chun Chia Cheng, Ai Sheng Ho, Chiung Fang Huang, Ling-Yun Chen, Chun Chao Chang, and Fu Der Mai
- Subjects
Materials science ,micelles ,Biophysics ,Pharmaceutical Science ,Mice, Nude ,Bioengineering ,Conjugated system ,Single-photon emission computed tomography ,Micelle ,Biomaterials ,chemistry.chemical_compound ,Mice ,International Journal of Nanomedicine ,Stomach Neoplasms ,Cell Line, Tumor ,Drug Discovery ,medicine ,Biomarkers, Tumor ,glucose-regulated protein 78 ,Animals ,Humans ,Particle Size ,Radionuclide Imaging ,Endoplasmic Reticulum Chaperone BiP ,Heat-Shock Proteins ,Original Research ,nuclear imaging ,Drug Carriers ,medicine.diagnostic_test ,gastric cancer ,Organic Chemistry ,Indium Radioisotopes ,Cancer ,General Medicine ,medicine.disease ,Thin-layer chromatography ,Molecular Imaging ,chemistry ,Biochemistry ,biomarker ,Heterografts ,Molecular imaging ,Radiopharmaceuticals ,Drug carrier ,Peptides ,Ethylene glycol - Abstract
Chun-Chia Cheng,1,2,* Chiung-Fang Huang,3,4,* Ai-Sheng Ho,5 Cheng-Liang Peng,6 Chun-Chao Chang,7,8 Fu-Der Mai,1,9 Ling-Yun Chen,10 Tsai-Yueh Luo,2 Jungshan Chang1,11,121Graduate Institute of Medical Sciences, Taipei Medical University, Taipei, 2Institute of Nuclear Energy Research, Atomic Energy Council, Taoyuan, 3School of Dental Technology, Taipei Medical University, Taipei, 4Division of Family and Operative Dentistry, Department of Dentistry, Taipei Medical University Hospital, Taipei, 5Division of Gastroenterology, Cheng Hsin General Hospital, Taipei, 6Institute of Biomedical Engineering, National Taiwan University, Taipei, 7Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taipei Medical University Hospital, Taipei, 8Department of Internal Medicine, Taipei Medical University, Taipei, 9Department of Biochemistry, Taipei Medical University, Taipei, 10Institute of Biochemistry and Biotechnology, Chung Shan Medical University, Taichung, 11Neuroscience Research Center, Taipei Medical University Hospital, Taipei, 12Research Center for Biomedical Implants and Microsurgery Devices, Taipei Medical University, Taipei, Taiwan*These authors contributed equally to this workAbstract: Increased expression of cellular membrane bound glucose-regulated protein 78 (GRP78) is considered to be one of the biomarkers for gastric cancers. Therefore, peptides or molecules with specific recognition to GRP78 can act as a guiding probe to direct conjugated imaging agents to localized cancers. Based on this rationale, GRP78-guided polymeric micelles were designed and manufactured for nuclear imaging detection of tumors. Thiolated GRP78 binding peptide (GRP78BP) was first labeled with maleimide-terminated poly(ethylene glycol)–poly(ε-caprolactone) and then mixed with diethylenetriaminepentaacetic acid (DTPA)-linked poly(ethylene glycol)–poly(ε-caprolactone) to form DTPA/GRP78BP-conjugated micelles. The coupling efficiency of micelles with radioisotope indium-111 (111In) was measured and analyzed by instant thin layer chromatography. The coupling efficiency of DTPA-conjugated micelles and DTPA/GRP78BP-conjugated micelles with 111In was 85% and 93%, respectively. For characterization and trace imaging, the radioisotope 111In-targeting tumors were detected and imaged in a xenograft murine model using nano single photon emission computed tomography/computed tomography. The results revealed that the radioactive intensity measured in the animals administered with GRP78BP-guided 111In-labeled micelles was statistically higher than that in animals administered with 111In-labeled micelles, demonstrating that GRP78BP more than doubled the accumulation of micelles to the tumor tissue (P < 0.05). The results indicate that the gastric cancer biomarker GRP78 is a probing target in the application of nuclear imaging for tumor diagnosis. This novel GRP78BP-guided micelle agent may be applied in clinical practice to complement the histological diagnosis.Keywords: biomarker, glucose-regulated protein 78, nuclear imaging, gastric cancer, micelles
- Published
- 2013
10. Abstract 3060: EGFR-mediated interleukin enhancer-binding factor 3 contributes to formation and survival of cancer stem-like tumorspheres through regulating HER3/ERBB3 expression as a therapeutic target against EGFR-positive non-small cell lung cancer
- Author
-
Ken-Hong Lim, Caleb Gon-Shen Chen, Kuei-Fang Chou, Ying-Wen Su, Jungshan Chang, Cheng-Wen Wu, Yu-Cheng Chang, Yi-Fang Chang, Ai-Sheng Ho, Nai-Wen Su, Chun-Chia Cheng, Huan-Chau Lin, and Cheng-Liang Peng
- Subjects
Cancer Research ,Gene knockdown ,biology ,Cell growth ,Afatinib ,Cancer ,medicine.disease ,Oncology ,Cancer stem cell ,Cancer cell ,medicine ,Cancer research ,biology.protein ,ERBB3 ,Epidermal growth factor receptor ,medicine.drug - Abstract
Objectives: YM155, an inhibitor of interleukin enhancer-binding factor 3 (ILF3), significantly suppresses cancer stemness property, implying that ILF3 contributes to cell survival of cancer stem cells. However, the molecular function of ILF3 inhibiting cancer stemness remain unclear. This study aimed to uncover the potential function of ILF3 involving in cell survival of epidermal growth factor receptor (EGFR)-positive lung stem-like cancer, and investigate the potential role to improve the efficacy of anti-EGFR therapeutics. Materials and Methods: The regulated association of EGFR and ILF3 was investigated at first. ILF3 was knockdowned and RNAseq was utilized to search for the putative genes regulated by ILF3. Meanwhile, HCC827- and A549-derived cancer stem-like cells were used to investigate the role of ILF3 in the formation of cancer stem-like tumorspheres. Results: We found that EGFR induced ILF3 expression, and YM155 reduced EGFR expression. The knockdown of ILF3 reduced not only EGFR expression in mRNA and protein levels, but also cell proliferation in vitro and in vivo, demonstrating that ILF3 was an oncoprotein contributing to cancer cell survival. Moreover, the knockdown and inhibition of ILF3 by shRNA and YM155, respectively, reduced the formation and survival of HCC827- and A549-derived tumorspheres through inhibiting HER3/ERBB3 expression, and synergized the therapeutic efficacy of afatinib, a tyrosine kinase inhibitor, against EGFR-positive A549 lung cells. Conclusion: This study demonstrated that ILF3 played an oncogenic role maintaining the EGFR-mediated cellular pathway as a therapeutic target to improve the therapeutic efficacy of afatinib. Therefore, we suggested that YM155, an ILF3 inhibitor, was potential for utilization in cancer therapy against the EGFR-positive cancers. Citation Format: Chun-Chia Cheng, Kuei-Fang Chou, Cheng-Wen Wu, Nai-Wen Su, Cheng-Liang Peng, Ying-Wen Su, Jungshan Chang, Ai-Sheng Ho, Huan-Chau Lin, Caleb Gon-Shen Chen, Yu-Cheng Chang, Ken-Hong Lim, Yi-Fang Chang. EGFR-mediated interleukin enhancer-binding factor 3 contributes to formation and survival of cancer stem-like tumorspheres through regulating HER3/ERBB3 expression as a therapeutic target against EGFR-positive non-small cell lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 3060.
- Published
- 2018
11. YM155 as an inhibitor of cancer stemness simultaneously inhibits autophosphorylation of epidermal growth factor receptor and G9a-mediated stemness in lung cancer cells
- Author
-
Cheng-Wen Wu, Ai Sheng Ho, Huan Chau Lin, Yu-Cheng Chang, Chun Chao Chang, Yi Fang Chang, Ken-Hong Lim, Chun Chia Cheng, Stanley Ching-Cheng Huang, Jungshan Chang, and Ling Huang
- Subjects
0301 basic medicine ,Lung Neoplasms ,Drug Evaluation, Preclinical ,Cancer Treatment ,Gene Expression ,lcsh:Medicine ,Biochemistry ,Lung and Intrathoracic Tumors ,0302 clinical medicine ,Histocompatibility Antigens ,Medicine and Health Sciences ,Growth factor receptor inhibitor ,Epidermal growth factor receptor ,Phosphorylation ,Post-Translational Modification ,lcsh:Science ,DNA methylation ,Multidisciplinary ,biology ,Chemistry ,Autophosphorylation ,Imidazoles ,Chemical Reactions ,Chemical Synthesis ,Chromatin ,ErbB Receptors ,Gene Expression Regulation, Neoplastic ,Nucleic acids ,Oncology ,030220 oncology & carcinogenesis ,Physical Sciences ,Epigenetics ,Reductive Methylation ,DNA modification ,Chromatin modification ,Research Article ,Chromosome biology ,Homeobox protein NANOG ,Cell biology ,Antineoplastic Agents ,Afatinib ,Research and Analysis Methods ,Methylation ,03 medical and health sciences ,Cancer stem cell ,Cell Line, Tumor ,Genetics ,medicine ,Humans ,RNA, Messenger ,Lung cancer ,A549 cell ,lcsh:R ,Cancers and Neoplasms ,Biology and Life Sciences ,Proteins ,Cancer ,Histone-Lysine N-Methyltransferase ,DNA ,medicine.disease ,030104 developmental biology ,Quinazolines ,Cancer research ,biology.protein ,lcsh:Q ,Secondary Lung Tumors ,Octamer Transcription Factor-3 ,Naphthoquinones - Abstract
Cancer stem cell survival is the leading factor for tumor recurrence after tumor-suppressive treatments. Therefore, specific and efficient inhibitors of cancer stemness must be discovered for reducing tumor recurrence. YM155 has been indicated to significantly reduce stemness-derived tumorsphere formation. However, the pharmaceutical mechanism of YM155 against cancer stemness is unclear. This study investigated the potential mechanism of YM155 against cancer stemness in lung cancer. Tumorspheres derived from epidermal growth factor receptor (EGFR)-mutant HCC827 and EGFR wild-type A549 cells expressing higher cancer stemness markers (CD133, Oct4, and Nanog) were used as cancer stemness models. We observed that EGFR autophosphorylation (Y1068) was higher in HCC827- and A549-derived tumorspheres than in parental cells; this autophosphorylation induced tumorsphere formation by activating G9a-mediated stemness. Notably, YM155 inhibited tumorsphere formation by blocking the autophosphorylation of EGFR and the EGFR-G9a-mediated stemness pathway. The chemical and genetic inhibition of EGFR and G9a revealed the significant role of the EGFR-G9a pathway in maintaining the cancer stemness property. In conclusion, this study not only revealed that EGFR could trigger tumorsphere formation by elevating G9a-mediated stemness but also demonstrated that YM155 could inhibit this formation by simultaneously blocking EGFR autophosphorylation and G9a activity, thus acting as a potent agent against lung cancer stemness.
- Published
- 2017
12. Abstract 934: EGFR induces ILF3 and G9a expressions to maintain Oct4-mediated stemness property in lung cancer
- Author
-
Cheng-Wen Wu, Chun-Chao Chang, Huan-Chau Lin, Ai-Sheng Ho, Chun-Chia Cheng, Jungshan Chang, Ken-Hong Lim, and Yi-Fang Chang
- Subjects
Homeobox protein NANOG ,Cancer Research ,Afatinib ,Cell ,Cancer ,Biology ,medicine.disease ,03 medical and health sciences ,0302 clinical medicine ,medicine.anatomical_structure ,Oncology ,Cancer stem cell ,Tumor progression ,030220 oncology & carcinogenesis ,Immunology ,medicine ,Cancer research ,biology.protein ,Epidermal growth factor receptor ,Lung cancer ,medicine.drug - Abstract
Cancer stem cells survive and lead to tumor recurrence in tumor therapeutic treatments. Lung cancer cells highly express epidermal growth factor receptor (EGFR), which is critical for tumor progression. We hypothesized that EGFR may play a pivotal role in the induction of cancer stemness cells (CSCs). The aim of this study attempted to investigate the molecular mechanism of EGFR-mediated cancer stemness, and to discover the potent therapeutic agents. A high expression level of cancer stemness markers, ALDH1, CD133, Oct4, and Nanog was observed in tumorspheres derived from HCC827. External EGF further elevated the expression of Oct4 in HCC827 cells. Moreover, chemical inhibition and genetic knockdown of EGFR reduced the Oct4 expression and also tumorsphere formation. We found that inhibitors targeting to EGFR (afatinib), ILF3 (YM155), and G9a (UNC0642) are potential to reduce the formations of tumorspheres. The results revealed that EGFR triggered the formation of tumorspheres through elevating the activations of G9a-mediated stemness genes. In addition, YM155 effectively inhibited tumor growth and formation of tumorspheres as an anti-lung cancer agent blocking the EGFR-G9a cell initiating program pathway. This study demonstrated that EGFR participated in maintain of cancer stemness property through expressing ILF3 and G9a expressions. YM155 inhibited the EGFR-G9a stemness pathway, and reduced the formation of tumorspheres as a potent anti-lung cancer agent. Citation Format: Chun-Chia Cheng, Jungshan Chang, Huan-Chau Lin, Ai-Sheng Ho, Ken-Hong Lim, Chun-Chao Chang, Yi-Fang Chang, Cheng-Wen Wu. EGFR induces ILF3 and G9a expressions to maintain Oct4-mediated stemness property in lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 934. doi:10.1158/1538-7445.AM2017-934
- Published
- 2017
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.